Clinical Trial Update: Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients. [Phase 4]

View source ↗

Summary

Phase 4 trial update for ledipasvir/sofosbuvir in hematopoietic stem cell transplant recipients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematopoietic Stem Cell Transplantation
• Hepatitis C

Drugs mentioned

• Ledipasvir/sofosbuvir (Ledipasvir and sofosbuvir)

Snippet

Sponsor: Kaiser Permanente | Conditions: Hematopoietic Stem Cell Transplantation | Phase 4 | Status: WITHDRAWN